BioMedSyn

Naproxen sodium/sumatriptan succinate is a combination medication indicated for the acute treatment of migraine with or without aura in adults and pediatric patients aged 12 to 17 years. It was launched in the early 2000s with the brand name Treximet to provide relief from moderate to severe migraine pain. Sumatriptan binds to 5-HT1B/1D receptors, resulting in cranial vessel constriction and inhibition of neuropeptide release. Naproxen exhibits analgesic, anti-inflammatory, and antipyretic properties through the inhibition of cyclooxygenase activity. The combination has demonstrated efficacy in providing significant headache pain relief and sustained pain-free periods in both adult and pediatric patients, with a decreased incidence of associated symptoms like photophobia, phonophobia, and nausea. It is more effective than placebo, sumatriptan, or naproxen sodium alone. The initial market launch aimed to provide a comprehensive approach to treating migraines, targeting both inflammation and neurovascular changes associated with migraine attacks. However, it is contraindicated in patients with ischemic or vasospastic coronary artery disease, following coronary artery bypass graft (CABG) surgery, and in patients with risk factors for cardiovascular events. Special precautions are outlined for its use in patients with hepatic impairment, hypertension, heart failure, medication overuse headache, serotonin syndrome, renal impairment, anaphylactic reactions, and in pregnant women. Overall, naproxen sodium/sumatriptan succinate is an effective option for the acute treatment of migraine in adults and pediatric patients, but caution should be exercised in certain patient populations and potential drug interactions should be considered.